Tungsten-based nanoparticles as contrast agents for liver tumor detection using dual-energy computed tomography-Reference-Cited by-同舟云学术

Tungsten-based nanoparticles as contrast agents for liver tumor detection using dual-energy computed tomography

Published:2023 Issue:24 Volume:11 Page:7817-7825
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Ji Xiuru¹,Zhu Lan²,Hsu Jessica C.³,Wang Han¹^ORCID,Zhou Jingwei⁴^ORCID,Wang Qingbing²,Li Yuhan¹,Cai Weibo³^ORCID,Ni Dalong¹^ORCID,Wu Zhiyuan²

Affiliation:

1. Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin 2nd Rd, Shanghai 200025, P. R. China

2. Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P. R. China

3. Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Wisconsin 53705, USA

4. Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Rd., Huangpu District, Shanghai 200011, People's Republic of China

Abstract

In this study, a novel class of CAs (i.e., WO3−x NPs) with excellent biocompatibility and minimal systemic toxicity for DECT was designed and presented a promising method for the accurate diagnosis of liver cancer.

Funder

National Natural Science Foundation of China

State Key Laboratory of High Performance Ceramics and Superfine Microstructure

University of Wisconsin-Madison

National Institutes of Health

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2023/BM/D3BM01068F

Reference42 articles.

1. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617

2. Cancer statistics, 2023

3. Rapidly liver-clearable rare-earth core–shell nanoprobe for dual-modal breast cancer imaging in the second near-infrared window

4. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

5. Chemical Factory‐Guaranteed Enhanced Chemodynamic Therapy for Orthotopic Liver Cancer